loading...| Preferred Name | Tamoxifen Citrate | |
| Synonyms |
|
|
| Definitions |
The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C855 |
|
| Accepted_Therapeutic_Use_For |
Breast cancer; Endometrial cancer; Gynecomastia; Melanoma; Ovarian cancer |
|
| ALT_DEFINITION |
A drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen citrate is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen citrate is a type of antiestrogen. |
|
| CAS_Registry |
54965-24-1 |
|
| CHEBI_ID |
CHEBI:9397 |
|
| Chemical_Formula |
C26H29NO.C6H8O7 |
|
| code |
C855 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC. |
|
| Display_Name |
Tamoxifen Citrate |
|
| FDA_UNII_Code |
7FRV7310N6 |
|
| Has_Free_Acid_Or_Base_Form | ||
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Tamoxifen Citrate |
|
| Legacy Concept Name |
Tamoxifen |
|
| Maps_To |
Tamoxifen Citrate |
|
| NCI_Drug_Dictionary_ID |
42901 |
|
| NSC Number |
180973 |
|
| PDQ_Closed_Trial_Search_ID |
42901 |
|
| PDQ_Open_Trial_Search_ID |
42901 |
|
| Preferred_Name |
Tamoxifen Citrate |
|
| prefixIRI |
NCIT:C855 |
|
| prefLabel |
Tamoxifen Citrate |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0700621 |
|
| subClassOf |